Sign up
Pharma Capital

SkinBioTherapeutics 'getting more confident' as it hits half-way point in human studies

Dr Cath O'Neill, chief executive of SkinBioTherapeutics PLC (AIM:SBTX), tells Proactive London's Andrew Scott there've been no safety or compliance concerns with people taking part in a test of the company’s skin cream.

Half the 120 volunteers have been through the trial process with the study set to complete as expected during this quarter.

Data yielded will be assessed to determine the effectiveness of the group’s SkinBiotix technology and whether it retains the same beneficial property of improving skin health when in a cream formulation.


View full SBTX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.